ENOV ENOVIS CORPORATION

Enovis™ Announces Leadership Change to International Surgical Business

Enovis™ Announces Leadership Change to International Surgical Business

Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025.

Visentin is a successful MedTech executive who comes to Enovis with more than 20 years of healthcare experience. Most recently, he was the Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit for BD, where he managed more than 700 employees across 50 countries and gained market share in a very competitive market. Prior to BD, Visentin served as Vice President and General Manager of Europe for Stryker’s Joint Replacement and Robotic Division, and Vice President, EMEA, for Johnson & Johnson Depuy Synthes.

“Under Benjamin Reinmann’s leadership, Enovis has created a world-class International Surgical Business. We sincerely thank Benjamin for his numerous contributions to the growth and success of both Enovis and Mathys, and especially throughout the critical integration of legacy companies Mathys and LimaCorporate,” said Louie Vogt, Group President of Enovis’ Reconstructive Business Group. “We are very excited to welcome Davide to Enovis. He is a dynamic leader with a strong track record of successfully growing businesses, a true passion for orthopedics, and the experience and playbook to take our business to the next level.”

Visentin has a degree in Computer Science from the University of Milan. He will primarily spend his time in Villanova, Italy, and Bettlach, Switzerland.

“We continue to make great progress with building and growing our International Surgical Business into a global orthopedics leader that is thriving because of our team’s commitment to excellence and to going above and beyond every day to create better together,” added Vogt. “The momentum we created in 2024 puts us in a strong position to advance our strategic goals, continue gaining market share and drive growth through innovation, all with the ultimate goal of improving patient outcomes.”

About Enovis



Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes and restore motion for life. We partner with the brightest minds in health to advance care that is smarter, personalized, and more effective, while improving operational efficiency for surgeons and clinicians around the world. Enovis solutions impact the well-being of millions of patients wherever they are on their pathway to health. Learn more about Enovis at .

Media Contact

Lee Griffin

Vice President, Global Marketing Communications & Digital, Enovis

+1 (469) 794-9760



EN
17/01/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the l...

 PRESS RELEASE

Enovis Announces Second Quarter 2025 Results

Enovis Announces Second Quarter 2025 Results Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2...

 PRESS RELEASE

Enovis to Host Second Quarter 2025 Results Conference Call on August 7...

Enovis to Host Second Quarter 2025 Results Conference Call on August 7th Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference C...

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time.Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meet...

 PRESS RELEASE

Enovis Announces First Quarter 2025 Results

Enovis Announces First Quarter 2025 Results Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch